Press Releases


May 20, 2015: The Fox Chase Chemical Diversity Center Announces it is Working Together With the Wistar Institute to Discover Inhibitors of Epstein Barr Nuclear Antigen EBNA1 for the Treatment of Epstein Barr Virus-Mediated Cancers

March 26, 2015: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I SBIR Grant Entitled “Pregnane X Receptor (PXR) Antagonists for Non-Alcoholic Fatty Liver Disease”

January 23, 2015: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Entitled “Development of Small Molecule Therapeutics Against RNA Viruses”

December 24, 2014: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Direct to Phase II SBIR Entitled “Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses”

September 3, 2014: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Entitled “Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV/AIDS”

May 17, 2014: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant From the National Heart, Lung, and Blood Institute Entitled “Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT”

August 23, 2013: The Fox Chase Chemical Diversity Center Announces that it Has Been Awarded a Phase I STTR Grant Together With Prof. Harvey Rubin of the University of Pennsylvania, “New Therapeutics for the Treatment of Acinetobactor baumannii Infections,” Totaling $300,000

June 27, 2013: The Fox Chase Chemical Diversity Center Announces that Promentis Pharmaceuticals Inc Has Engaged FCCDC To Conduct Medicinal Chemistry Efforts

June 24, 2013: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a 2-Year Phase II SBIR Grant Totaling $1,919,714

More

Press Releases


May 11, 2015: The Fox Chase Chemical Diversity Center Announces that is Has Established a Strategic Partnership With the Prestigious Wistar Institute

February 2, 2015: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I SBIR Grant Entitled “Development of Drugs that Target the M2 Proton Channel from Influenza Virus”

December 29, 2014: The Fox Chase Chemical Diversity Center Announces it Has Received a $100,000 Keystone Innovation Zone Tax Credit from the Department of Community & Economic Development of the Commonwealth of Pennsylvania

September 8, 2014: The Fox Chase Chemical Diversity Center Will Be Presenting Riluzole Prodrugs to Treat ALS and Melanoma, Funded by a Phase II SBIR Grant, at the NCI SBIR Investor Forum on Nov. 13 in Santa Clara, CA

June 16, 2014: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded A Phase II SBIR Grant With the Title “A Novel Therapeutic for Invasive Candidiasis”

December 31, 2013: The Fox Chase Chemical Diversity Center Announces it HasSubmitted it's 3,000th Small Molecule Test Compound

August 23, 2013: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II SBIR Grant, "Development of Small Antimicrobial Peptide Mimics,” Totaling $2,000,000

July 22, 2013: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Small Business Phase I STTR Grant Entitled DC-SIGN Inhibitors for the Treatment of HIV Infection for $300,000

Septermber 14, 2012: The Fox Chase Chemical Diversity Center Announces the Receipt of a Chemistry Sub-Award From an R21 Grant with Temple University

More

Selected Recent Publications

Rubin, H.; Selwood, T.; Yano, T.; Weaver, D. G.; Loughran, H. M.; Costanzo, M. J.; Scott, R. W.; Wrobel, J. E.; Freeman, K. B.; Reitz, A. B. Acinetobacter baumannii OxPhos inhibitors as selective anti-infective agents. Bioorg. Med. Chem. Lett. 2015, 25, 378-383.

Pelletier, J. C.; Velvadapu, V.; McDonnell, M. E.; Wrobel, J. E.; Reitz, A. B. Intramolecular rearrangement of -amino acid amide derivatives of 2-aminobenzothiazoles. Tetrahedron Lett. 2014, 55, 4193-4195.

Han, Z.; Lu, J.; Liu, Y.; Davis, B.; Lee, M. S.; Olson, M. A.; Ruthel, G.; Freedman, B. D.; Schnell, M. J.; Wrobel, J. E.; Reitz, A. B.; and Harty, R. N. Small Molecule Probes Targeting the Viral PPxY-Host Nedd4 Interface Block Egress of a Broad Range of RNA Viruses. Journal of Virology, 2014, 88, 7294-7306.

McDonnell, M. E.; Bian, H.;Wrobel, J.; Smith, G. R.; Liang, S.; Ma, H.; Reitz, A. B. Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors. Bioorg Med Chem Lett. 2014, 24, 1116-1121.

Caglic, D.; Krutein, M. C.; Bompiani, K. M.; Barlow, D. J.; Benomi, G.; Pelletier, J. C.; Reitz, A. B.; Lairson, L. L.; Houseknecht, K. L.; Smith, G. R.; Dickerson, T. J. Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain. J. Med. Chem. 2014, 57, 669-676.

Smith, G. R.; Brenneman, D. E.; Zhang, Y.; Du, Y.; Reitz, A. B. Small-Molecule Anticonvulsant Agents with Potent In Vitro Neuroprotection and Favorable Drug-Like Properties. J. Mol. Neurosci. 2014, 52, 446-458.

Gregg, R. A.; Tallarida, C. S.; Reitz, A. B.; McCurdy, C.; Rawls, S. M. Mephedron (4-methylmethcathinone), a principal constituent of psychoactive bath salts, produces behavioral sensitization in rats. Drug Alcohol Depend. 2013, 133, 746-750.

Gregg, R. A.; Tallarida, C. S.; Reitz, A. B.; Rawls, S. M. Mephedrone interactions with cocaine: prior exposure to the ‘bath salt’ constituent enhances cocaine-induced locomotor activation in rats. Behavioural Pharmacology 2013, 24, 684-688.

Watterson, D. M.; Grum-Tokars, V. L.; Roy, S. M.; Schavocky, J. P.; Bradaric, B. D.; Bachstetter, A. D.; Xing, B.; Dimayuga, E.; Saeed, F.; Zhang, H.; Staniszewski, A.; Pelletier, J. C.; Minasov, G.; Anderson, W. F.; Arancio, O.; Van Eldick, L. J. Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. PLoS ONE 2013, 8(6), e66226.

Ramoz, L.; Lodi, S.; Bhatt, P.; Reitz, A. B.; Tallarida, C.; Tallarida, R. J.; Raffa, R. B.; Rawls, S. M. Mephedrone ('Bath Salt') Pharmacology: Insights from Invertebrates, Neuroscience, 2012, 208, 79-84.

Lisek, R.; Yuvasheva, E.; Chiu, Y. T.; Reitz, A. B.; Liu-Chen, L. Y.; Rawls, S. M. Mephedrone (‘Bath Salt’) Elicits Conditioned Place Preference and Dopamine-Sensitive Locomotor-Sensitive Activation. Drug and Alcohol Dependence, 2012, 126, 257-262.

Cassel, J. A.; Ilyin, S.; McDonnell, M. E.; Reitz, A. B. Novel Inhibitors of Heat Shock Protein Hsp70-Mediated Luciferase Refolding that Bind to DnaJ, Bioorg. Med. Chem. Lett. 2012, 20, 3609-3614.

Cassel, J. A.; McDonnell, M. E.; Velvadapu, V.; Andrianov, V.; Reitz, A. B. The effects of small molecule inhibitors of nucleic acid binding to TDP-43 on TDP-43 metabolism and function. Biochimie, 2012, 94, 1974-1981.

Smith, G. R.; Caglič, D.; Čapek, P.; Zhang, Y.; Godbole, S.; Reitz, A. B.; Dickerson, T. J. Reexamining hydroxamate inhibitors of Botulinum neurotoxin serotype A: Extending towards the b-exosite. Bioorg. Med. Chem. Lett. 2012, 22, 3754-3757.

McDonnell, M. E.; Vera, M. D.; Blass, B. E.; Pelletier, J. C.; King, R. C.; Fernandez-Metzler, C.; Smith, G. R.; Wrobel, J.; Chen, S.; Reitz, A. B. Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling. 2012, Bioorg. Med. Chem., 20, 5642-5648.

Velvadapu, V., McDonnell, M. E., Jaffe, E. K., Reitz, A. B.  Facile Synthesis of Mutagen X (MX): 3-Chloro-4-(dichloromethyl)-5-hydroxy-5H-furan-2-one. Tetrahedron Letters, 2012, 53, 3144-3146.

Brenneman, D. E.; Smith, G. R.; Zhang, Y.; Du, Y.; Kondaveeti, S. K.; Zdilla, M. J.; Reitz, A. B.  Small-Molecule Anticonvulsant Agents with Potent in vitro Neuroprotection. J. Molecular Neuroscience, 2012, 47, 368-379.

Venkatesh, M., Wang, H., Cayer, J., Leroux, M., Salvail, D., Das, B., Wrobel, J., Mani, S. In Vivo and In Vitro Characterization of a Frist-in-Class Novel Azole Analog That Targets Pregnane X Receptor Activation. Molecular Pharmacology, 2011, 80, 124-135.

Čapek, P., Zhang, Y., Barlow, D.J., Houseknecht, K.L., Smith, G., Dickerson, T.J. Enhancing the Pharmacokinetic Properties of Botulinum Neurotoxin Serotype A Protease Inhibitors through Rational Design. ACS Chemical Neuroscience, 2011, 2, 288-293.

Reitz, A. B.; Ramirez, U. D.; Stith, L.; Du, Y.; Smith, G. R.; Jaffe, E. K. Pseudomonas aeruginosa Porphobilinogen Synthase Assembly State Regulators: Hit Discovery and Initial SAR Studies. ARKIVOC, 2010, 175-188.

Reitz, A. B.; Smith, G. R.; Tounge, B. A.; Reynolds, C. H. Hit Triage Using Efficiency Indices after Screening of Compound Libraries in Drug Discovery. Curr. Top. Med. Chem., 2009, 9, 1718-1724.